Fogarty et al More on COVID Coagulopathy in Caucasians.pdf (448.2 kB)

More on COVID-19 coagulopathy in Caucasian patients

Download (448.2 kB)
journal contribution
posted on 19.05.2021, 15:59 by Helen FogartyHelen Fogarty, Liam Townsend, Clíona Ní Cheallaigh, Colm Bergin, Ignacio Martin-Loeches, Paul Browne, Christopher L Bacon, Richard Gaule, Alexander Gillett, Mary Byrne, Kevin Ryan, Niamh O'Connell, Jamie O'SullivanJamie O'Sullivan, Niall Conlon, James O'DonnellJames O'Donnell

We are grateful for the comments of Marrietta et al.1 and welcome the opportunity to provide further details on the coagulopathy observed in our patients with coronavirus disease 2019 (COVID‐19) infection.2 The weight‐adjusted low‐molecular‐weight heparin (LMWH) thromboprophylaxis used in the study is that routinely used for hospital in‐patients in our institution, consistent with national recommendations.3, 4 With respect to the cohort of patients with COVID‐19 enrolled in our study, it is important to highlight that 74% of patients received enoxaparin 40 mg (4000 iu) subcutaneously once daily. In 12% of patients, the dose of enoxaparin was reduced to 20 mg once daily due to a weight of < 50 kg (8%) or renal impairment (4%). In all, 11% of our cohort were already on extended‐duration therapeutic anticoagulation at time of presentation with COVID‐19 for a variety of reasons (including atrial fibrillation, mitral valve replacement, and cancer‐associated venous thromboembolism) and consequently were maintained on the same during their admissions. Finally, 2% of patients did not receive thromboprophylaxis due to perceived increased bleeding risks. Of particular importance in respect to the point raised by Marrietta et al.1, only one patient with COVID‐19 actually received an enoxaparin dose of > 40 mg for thromboprophylaxis (due to increased body weight of > 100 kg). In summary therefore, the doses of LWMH used in our cohort are entirely consistent with best practice guidelines. In addition, none of our cohort developed any major bleeding or clinically relevant non‐major bleeding complications.5, 6


History

Comments

This is the peer reviewed version of the following article: Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, Bacon CL, Gaule R, Gillett A, Byrne M, Ryan K, O'Connell N, O'Sullivan JM, Conlon N, O'Donnell JS. More on COVID-19 coagulopathy in Caucasian patients. British Journal of Haematology. 2020;189(6):1060-1061, which has been published in final form at https://doi.org/10.1111/bjh.16791. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Published Citation

Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, Bacon CL, Gaule R, Gillett A, Byrne M, Ryan K, O'Connell N, O'Sullivan JM, Conlon N, O'Donnell JS. More on COVID-19 coagulopathy in Caucasian patients. British Journal of Haematology. 2020;189(6):1060-1061.

Publication Date

25 May 2020

PubMed ID

32400024

Department/Unit

  • Irish Centre for Vascular Biology
  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Vascular Biology
  • Health Professions Education
  • Cancer
  • Immunity, Infection and Inflammation

Publisher

Wiley

Version

  • Accepted Version (Postprint)